PT  - JOURNAL ARTICLE
AU  - Dewald, Felix
AU  - Pirkl, Martin
AU  - Ahmadov, Elvin
AU  - Paluschinski, Martha
AU  - Kühn, Joachim
AU  - Elsner, Carina
AU  - Schulte, Bianca
AU  - Schlotz, Maike
AU  - Oral, Göksu
AU  - Knüfer, Jacqueline
AU  - Bernhard, Michael
AU  - Michael, Mark
AU  - Luxenburger, Maura
AU  - Andrée, Marcel
AU  - Hennies, Marc Tim
AU  - Hafezi, Wali
AU  - Müller, Marlin Maybrit
AU  - Kümpers, Philipp
AU  - Risse, Joachim
AU  - Kill, Clemens
AU  - Manegold, Randi Katrin
AU  - Frantzki, Ute von
AU  - Richter, Enrico
AU  - Emmert, Dorian
AU  - Monzon-Posadas, Werner O.
AU  - Gräff, Ingo
AU  - Kogej, Monika
AU  - Büning, Antonia
AU  - Baum, Maximilian
AU  - Teipel, Finn
AU  - Mochtarzadeh, Babak
AU  - Wolff, Martin
AU  - Gruell, Henning
AU  - Cristanziano, Veronica Di
AU  - Burst, Volker
AU  - Streeck, Hendrik
AU  - Dittmer, Ulf
AU  - Ludwig, Stephan
AU  - Timm, Jörg
AU  - Klein, Florian
TI  - Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
AID  - 10.1101/2022.12.31.22284088
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.12.31.22284088
4099  - http://medrxiv.org/content/early/2023/01/03/2022.12.31.22284088.short
4100  - http://medrxiv.org/content/early/2023/01/03/2022.12.31.22284088.full
AB  - Determining SARS-CoV-2 immunity is critical to assess COVID-19 risk and the need for prevention and mitigation strategies. We measured SARS-CoV-2 Spike/Nucleocapsid seroprevalence and serum neutralizing activity against Wu01, BA.4/5 and BQ.1.1 in 1,411 individuals who received medical treatment in five emergency departments in North Rhine-Westphalia, Germany. We detected Spike-IgG in 95.6%, Nucleocapsid-IgG in 24.0% and neutralization against Wu01, BA.4/5 and BQ.1.1 in 94.4%, 85.0%, and 73.8% of participants, respectively. Neutralization against BA.4/5 and BQ.1.1 was reduced 5.6- and 23.4-fold compared to Wu01. Accuracy of S-IgG detection for determination of neutralizing activity against BQ.1.1 was reduced substantially. Furthermore, we explored previous vaccinations and infections as most important correlates of improved BQ.1.1 neutralization using multivariable and Bayesian network analyses. Given an adherence to COVID-19 vaccination recommendations of only 67.7% of all participants, we highlight the need for improvement of vaccine-uptake to reduce the COVID-19 risk in upcoming infection-waves with immune evasive variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the ministry for work, health, and social affairs of the state of North Rhine-Westphalia (CPS-1-1F).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples and data were obtained under protocols approved by the ethics committees of the Medical Faculty of the University of Cologne (22_1262), of the Medical Faculty of the University of Bonn (314/22), of the Medical Faculty of the University of Duesseldorf (2022-2072), of the Medical Faculty of the University of Essen (22-10838-BO), and of the Medical Faculty of the University of Muenster (2022-490-b-S). All participants provided written informed consent. This study was registered as clinical trial (DRKS00029414).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors